Document Detail


Nationwide Improvements in Survival From Out-of-Hospital Cardiac Arrest in Japan.
MedLine Citation:
PMID:  23035209     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Little is known about the nationwide trend in the survival of out-of-hospital cardiac arrest (OHCA) in Japan and the differences in incidence and survival by age group and origin of arrest. METHODS AND RESULTS: A nationwide, prospective, population-based observation covering the whole population of Japan and involving consecutive OHCA patients with resuscitation attempts has been conducted from January 2005 to December 2009. The main outcome measure was one-month survival with favorable neurological outcome. The nationwide trend in OHCA incidence and outcome by age and origin were assessed. Multiple logistic regression analysis for bystander-witnessed OHCA was used to adjust for factors that were potentially associated with favorable neurological outcome. During 5-years, 547,153 overall OHCAs and 169,360 bystander-witnessed OHCAs were enrolled. The annual incidence significantly increased among overall OHCAs and bystander-witnessed OHCAs. Neurologically favorable survival significantly increased from 1.6% (1676/102,737) in 2005 to 2.8% (3280/115,250) in 2009 (P<0.001), from 2.1% (638/30,556) to 4.3% (1558/36,361) (P<0.001), from 9.8% (437/4461) to 20.6% (1215/5906) (P<0.001) among overall OHCA, bystander-witnessed OHCA, and bystander-witnessed ventricular fibrillation OHCA, respectively. Public-access automated external defibrillator use, either bystander-initiated chest compression-only cardiopulmonary resuscitation (CPR) or conventional CPR, and earlier EMS response time were associated with a better neurological outcome. Favorable neurological outcome among adult OHCAs significantly improved, but the outcome among younger children and very elderly did not improve and was dismal irrespective of origin of OHCA. CONCLUSIONS: The nationwide improvements of favorable neurological outcome from OHCA were observed in Japan, and differed by age group and origin of OHCA.
Authors:
Tetsuhisa Kitamura; Taku Iwami; Takashi Kawamura; Masahiko Nitta; Ken Nagao; Hiroshi Nonogi; Naohiro Yonemoto; Takeshi Kimura
Related Documents :
16144929 - Phase i combining a p-glycoprotein inhibitor, ms209, in combination with docetaxel in p...
11441409 - Phase iii randomized trial of docetaxel in combination with cisplatin or carboplatin or...
20539209 - Phase ii trial of oxaliplatin and capecitabine after progression to first-line chemothe...
16891869 - Phase ii evaluation of docetaxel plus exisulind in patients with androgen independent p...
12712259 - Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-s...
19331199 - Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiot...
16527479 - Yttrium-90 internal radiation therapy for hepatic malignancy.
83129 - Surgical treatment of adenocarcinoma. location: junction of the right, left, and common...
18579399 - A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-3
Journal Detail:
Title:  Circulation     Volume:  -     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1 Kyoto University Health Service, Kyoto, Japan;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12...
Next Document:  Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evi...